A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects
with metastatic castration resistant prostate cancer (CRPC) as reflected by the
prostate-specific antigen (PSA) response.